364 related articles for article (PubMed ID: 32089685)
1. EGFR
Rutkowska A; Stoczyńska-Fidelus E; Janik K; Włodarczyk A; Rieske P
J Oncol; 2019; 2019():1092587. PubMed ID: 32089685
[TBL] [Abstract][Full Text] [Related]
2. Low Incidence along with Low mRNA Levels of
Peciak J; Stec WJ; Treda C; Ksiazkiewicz M; Janik K; Popeda M; Smolarz M; Rosiak K; Hulas-Bigoszewska K; Och W; Rieske P; Stoczynska-Fidelus E
J Cancer; 2017; 8(1):146-151. PubMed ID: 28123609
[No Abstract] [Full Text] [Related]
3. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.
Szabó B; Nelhubel GA; Kárpáti A; Kenessey I; Jóri B; Székely C; Peták I; Lotz G; Hegedus Z; Hegedus B; Füle T; Döme B; Tímár J; Tóvári J
Oral Oncol; 2011 Jun; 47(6):487-96. PubMed ID: 21498106
[TBL] [Abstract][Full Text] [Related]
4. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.
Theodoropoulou M; Arzberger T; Gruebler Y; Jaffrain-Rea ML; Schlegel J; Schaaf L; Petrangeli E; Losa M; Stalla GK; Pagotto U
J Endocrinol; 2004 Nov; 183(2):385-94. PubMed ID: 15531726
[TBL] [Abstract][Full Text] [Related]
5. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
7. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
8. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
9. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
10. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
11. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
12. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation.
Yamamoto K; Takahashi K; Shiozaki K; Yamaguchi K; Moriya S; Hosono M; Shima H; Miyagi T
PLoS One; 2015; 10(3):e0120578. PubMed ID: 25803810
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
[TBL] [Abstract][Full Text] [Related]
15. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
18. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
19. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface.
Mehrabi M; Mahdiuni H; Rasouli H; Mansouri K; Shahlaei M; Khodarahmi R
Int J Biol Macromol; 2018 Aug; 115():401-417. PubMed ID: 29665393
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti A; Loeffler JS; Dyson NJ
Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
